Trial record 1 of 1 for:
XPORT-DLBCL-025
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04607772 |
|
Recruitment Status :
Suspended
(Sponsor decision)
First Posted : October 29, 2020
Last Update Posted : January 25, 2023
|
Sponsor:
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2. The Phase 1 of the study will be a standard 3 + 3 dose escalation to determine the maximal tolerated dose (MTD), recommended Phase 2 dose (RP2D) for each treatment arm, and assess the dose limiting toxicities (DLTs). The Phase 2 of the study will be a dose expansion study to assess the efficacy and safety of for RP2D selected at the end of Phase 1 of the study for each treatment arm.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Drug: Selinexor Drug: Rituximab Drug: Bendamustine Drug: Polatuzumab Vedotin Drug: Ibrutinib Drug: Lenalidomide Drug: Tafasitamab Drug: Venetoclax Drug: Gemcitabine Drug: Oxaliplatin | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 350 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
| Actual Study Start Date : | November 18, 2020 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Lymphoma
Drug Information available for:
Selinexor
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm A: Selinexor with Bendamustine and Rituximab (S-BR))
Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Bendamustine Dose: 90 mg/m^2 |
|
Experimental: Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Polatuzumab Vedotin Dose: 1.8 mg/kg |
|
Experimental: Arm C: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment for Cycle 1 to 6.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Bendamustine Dose: 90 mg/m^2 Drug: Polatuzumab Vedotin Dose: 1.8 mg/kg |
|
Experimental: Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1 and 3 for Cycle 1 to 6 (each cycle consists of 14 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Gemcitabine Dose: 1000 mg/m^2 Drug: Oxaliplatin Dose: 100 mg/m^2 |
|
Experimental: Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Ibrutinib Dose: 420, 560 mg |
|
Experimental: Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Lenalidomide Dose: 20, 25 mg |
|
Experimental: Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Lenalidomide Dose: 20, 25 mg Drug: Tafasitamab Dose: 12 mg/kg |
|
Experimental: Arm H: Selinexor with Venetoclax (S-V)
Participants will receive 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8 and 15 for Cycle 1 to 6 of primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-5) during continuous treatment (28 days per cycle). Participants who received 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for Cycle 1; 400 mg daily for Cycle 2 to 6. Participants who received 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6. Participants who received 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6. Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Venetoclax Dose: 200, 400, 600, 800 mg |
Primary Outcome Measures :
- Phase 1: Maximum Tolerated Dose (MTD) [ Time Frame: Within the first cycle (maximum 28 days) of treatment ]
- Phase 1: Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 6 cycles (up to 6 months) of treatment ]
- Phase 2: Overall Response Rate (ORR) per the Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
Secondary Outcome Measures :
- Phase 1: Overall Response Rate per the Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
- Phase 1: Disease Control Rate (DCR) per Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) ]
- Phase 1: Duration of Response (DOR) per Lugano Classification 2014 [ Time Frame: Time from the first response of PR or CR until disease progression (up to 12 months) ]
- Phase 1: Overall Response Rate (ORR) per the Modified Lugano Classification [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR (up to 6 months) ]
- Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity [ Time Frame: From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) ]
- Phase 2: Overall Response Rate per the Modified Lugano Classification [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
- Phase 2: Disease Control Rate (DCR) per Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) ]
- Phase 2: Duration of Response (DOR) per Lugano Classification 2014 [ Time Frame: Time from the first response of PR or CR until disease progression or death (up to 12 months) ]
- Phase 2: Number of Participants With AEs by Occurrence, Nature, and Severity [ Time Frame: From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants greater than or equal to (≥) 18 years of age.
- Have pathologically confirmed relapsed/refractory (RR) DLBCL, not otherwise specified (NOS).
- Participants with High Grade B-cell Lymphoma (HGBL) are allowed in Phase 2 only.
-
Prior lines of systemic therapy for the treatment of DLBCL:
- For Arms A, B, C, E, F, G, H: Participants must have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL.
- For Arm D (S-R-GemOx) participants must have received at least 1 but not more than 2 lines of systemic therapy.
- Positron emission tomography (PET) positive measurable disease per the Lugano Classification 2014, having at least 1 node with longest diameter (LDi) greater than (>) 1.5 centimetres (cm) or 1 extranodal lesion with LDi >1 cm.
- Adequate bone marrow function at Screening.
- Circulating lymphocytes less than or equal to (≤) 50 * 109/L.
- Adequate liver and kidney function.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- An estimated life expectancy of >6 months at Screening.
- Participants with primary refractory disease defined as no response or relapse within 6 months after ending first-line treatment will be allowed on study (up to 20 percentage [%] of enrolled participants in each Phase).
- Male participants, and female participants of childbearing potential must agree to use highly effective methods of contraception during the duration of the study and will continue following the last dose of study treatment for the longest duration stated on the label of each of the given drugs (depending on each arm).
- Female participants of childbearing potential must have a negative serum pregnancy test at Screening. Female participants of childbearing potential in the S-LR arm and the S-LT arm must have 2 negative pregnancy tests before Lenalidomide treatment (Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy).
- Participants with active hepatitis B Virus (HBV) are eligible if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 international units per milliliter (IU/mL); participants with untreated hepatitis C Virus (HCV) are eligible if viral load is negative per institutional standard; participants with human immunodeficiency virus (HIV) are eligible if cluster of differentiation 4 (CD4+) T-cell counts ≥350 cells per microliter (cells/μL), viral load is negative and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year.
Exclusion Criteria:
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma; composite lymphoma (Hodgkin lymphoma + NHL); Gray zone lymphoma; DLBCL transformed from Chronic Lymphocytic Leukemia (Richter Syndrome); Primary mediastinal large B-cell lymphoma (PMBCL); T-cell rich large B-cell lymphoma.
- Previous treatment with selinexor or other XPO1 inhibitors.
- Contraindication to any drug contained in the different treatment arms.
- Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to Cycle 1 Day 1 (C1D1). Low dose steroids <30 mg prednisone (or equivalent) and palliative radiotherapy are permitted.
- Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to Day 1 dosing or strong CYP3A inducers ≤14 days prior to Day 1 dosing.
- Any AE, by Cycle 1 Day 1 (C1D1), which has not recovered to Grade ≤1 (CTCAE, v. 5.0), or returned to baseline, related to the previous DLBCL therapy, except alopecia.
- Major surgery <14 days of C1D1.
- Autologous stem cell transplant (SCT) <100 days or allogeneic SCT <180 days prior to C1D1 or active graft-versus-host disease after allogeneic SCT (or cannot discontinue graft versus host disease [GVHD] treatment or prophylaxis).
- Prior chimeric antigen receptor T cell (CAR-T cell) infusion at any time (Phase 1 only); prior CAR-T cell infusion ≤120 days prior to C1D1 (Phase 2 only).
- Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, or able to comply with the study procedures.
- Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
- Inability to swallow tablets, malabsorption syndrome, or any other GI disease or dysfunction that could interfere with absorption of study treatment.
- Breastfeeding women or pregnant women.
- Inability or unwillingness to sign informed consent form.
- In the opinion of the Investigator, participants who are below their ideal body weight and would be unduly impacted by changes in their weight.
-
Known allergy to any of the drug planned to be given.
The following are Arm Specific exclusion criteria:
- Arm B (S-PR): Serum total bilirubin >1.5 * ULN, Neuropathy Grade ≥2 (CTCAE, v5.0).
- Arm C (S-PBR): Serum total bilirubin >1.5 * ULN, Neuropathy Grade ≥2 (CTCAE, v5.0).
- Arm D (S-R-GemOx): Neuropathy Grade 2≥ (CTCAE, v5.0) interstitial lung disease or pulmonary fibrosis.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04607772
Locations
Show 18 study locations
Sponsors and Collaborators
Karyopharm Therapeutics Inc
| Responsible Party: | Karyopharm Therapeutics Inc |
| ClinicalTrials.gov Identifier: | NCT04607772 |
| Other Study ID Numbers: |
XPORT-DLBCL-025 |
| First Posted: | October 29, 2020 Key Record Dates |
| Last Update Posted: | January 25, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Karyopharm Therapeutics Inc:
|
Karyopharm Diffuse Large B-Cell Lymphoma DLBCL KPT-330 Selinexor Bendamustine Rituximab |
Polatuzumab Vedotin Gemcitabine Oxaliplatin Ibrutinib Lenalidomide Tafasitamab Venetoclax |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Gemcitabine Rituximab Oxaliplatin Lenalidomide Venetoclax |
Bendamustine Hydrochloride Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents |